Why is this consultation important?
The PSA reviews the General Pharmaceutical Council together with nine other statutory healthcare regulators against their Standards of Good Regulation.
The GPhC has failed to meet 100% of the required standards since 2018 and this is a matter of serious concern. In many cases, the findings in the PSA published reports are the only mechanism by which members of the profession and members of the public become aware of issues of concern related to the way in which the GPhC carries out its regulatory duties.
The PDA will be responding to this consultation and will want to be assured that any changes to the process will in no way reduce the robustness of the scrutiny which they currently bring to bear on the regulators which they review.
Members can find more details and a link to the consultation document here.
Members are encouraged to respond to the consultation directly or to forward their comments to the PDA at consultations@the-PDA.org so that they can be included in discussions and drafting of the PDA response. If sending comments to the PDA, please do so by 12 February 2021.
This consultation closes on 4 March 2021.